The efficacy of a “cocktail therapy” on Parkinson’s disease with dementia

References

• Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson‘s patients in the UK. The CamPaIGN study. Brain. 2004;127:550–560. doi:10.1093/brain/awh06714691062
   PubMed Web of Science ®Google Scholar
• Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol. 2012;25(4):208–214. doi:10.1177/089198871246482323172765
   PubMed Web of Science ®Google Scholar
• PD and dyskinesia groups of Chinese medical association-neurology branch, neuropsychology and behavioural neurology groups of Chinese medical association-neurology branch. Guidance for diagnosis and treatment of PDD. Zhonghuashenjingkezazi. 2011;44(9):635–637.
   Google Scholar
• Emre M, Tsolaki M, Bonuccelli U, et al. 11018 study investigators. Memantine for patients with Parkinson‘s disease dementia or dementia with lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–977. doi:10.1016/S1474-4422(10)70194-020729148
   PubMed Web of Science ®Google Scholar
• Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson‘s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314–2324. doi:10.1002/mds.2184418098298
   PubMed Web of Science ®Google Scholar
• Jia J, Wei C, Liang J, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: a multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement. 2016;12(2):89–99. doi:10.1016/j.jalz.2015.04.01026086183
   PubMed Web of Science ®Google Scholar
• Guo T, Shen RL, Wu YZ, Teng JF. The effect of dl-butylphthalide on NR2B and synaptophysin in hippocampus of aged rats after chronic cerebral hypoperfusion. Zhongguo Shiyong Shenjingjibing Zazhi. 2007;10:60–62.
   Google Scholar
• Peng Y, Sun J, Hon S, et al. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer‘s disease. J Neurosci. 2010;30(24):8180–8189. doi:10.1523/JNEUROSCI.0340-10.201020554868
   PubMed Web of Science ®Google Scholar
• Hu D, Zhang LY, Feng YP. Effect of dl-3-n-butylphthalide on memory disturbance induced by focal cerebral ischemia in rats. Zhongguo Yaoxue yu Dulixue Zazhi. 1997;11:14–16.
   Google Scholar
• Guo YX. The efficacy observation for combination of oxiracetam and nimodipine in treating vascular dementia. Dangdai Yixue. 2013;19(2):136–137.
   Google Scholar
• Xu YS. The clinical research for combination of nimodipine and oxiracetam in treating vascular dementia. Zhongguo Yixue Gongcheng. 2014;22(2):160–162.
   Google Scholar
• Rojas P, Montes P, Rojas C, Serrano-García N, Rojas-Castañeda JC. Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson‘s disease: therapeutic perspectives. Nutrition. 2012;28(11–12):1081–1088. doi:10.1016/j.nut.2012.03.00722817828
   PubMed Web of Science ®Google Scholar
• Zhang C, Feng J, Li HJ, Wang JQ, Ye JQ, Wang XJ. The efficacy observation for ginkgo biloba extract in treating mild cognitive impairment of PD. Zhongguo Xiandai Yisheng. 2013;51(31):109–111.
   Google Scholar
• Zeng CM, Zhao W, Ding N, Zeng CQ. The research progress for action mechanism of ginkgo biloba extract in treating neurodegenerative disease. Zhongguo Heli Yongyao Tansuo. 2013;10(8):21–23.
   Google Scholar
• Feng JJ, Li YL, Hou C, Li LB, Zhang QJ. The protection function of ginkgo biloba extract to dopaminergic neuron of the model rat with PD. Xi‘An Jiaotong Daxue Xuebao Yixueban. 2011;32(6):783–786.
   Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson‘s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–184.1564476
   PubMed Web of Science ®Google Scholar
• Dyskinesia and PD groups of Chinese medical association-neurology branch. Diagnosis of PD. Zhonghuashenjingkezazi. 2006;39(6):408–409.
   Google Scholar
• Chen L, Liu WG, Zhao YY, Hua P, Wang Y, Zhang N. Application value of MoCA in treating the patients with PD cognitive disorde. Zhonghuashenjingkezazi. 2011;44(3):200–202.
   Google Scholar
• Zhao MM, Chen WX. Epidemiology and hazard factors of PDD. Jiangsu Yiyao. 2013;39(6):710–712.
   Google Scholar
• Liu JA. Research progress for mild cognitive impairment of PD. Jiefangjun Yixueyuan Xuebao. 2014;35(2):199.
   Google Scholar
• Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson‘s disease. Biochim Biophys Acta. 2010;1802(1):29–44. doi:10.1016/j.bbadis.2009.08.01319733240
   PubMed Web of Science ®Google Scholar
• Yang ZM, Li XZ, Lu F, Liu SM. The research progress for mitochondria pathogenesis of PD. Zhongguo Laonianxue Zazhi. 2014;34(21):6233–6235.
   Google Scholar
• Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson‘s disease. J Neurol Neurosurg Psychiatry. 1999;67(4):492–496.10486397
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with lewy bodies and Parkinson‘s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528–536.11376470
   PubMed Web of Science ®Google Scholar
• Poewe W, Gauthier S, Aarsland D, et al. Diagnosis and management of Parkinson‘s disease dementia. Int J Clin Pract. 2008;62(10):1581–1587. doi:10.1111/j.1742-1241.2008.01869.x18822028
   PubMed Web of Science ®Google Scholar